The Global Protein Therapeutics Market: Market Dynamics and Pipeline Analysis


December 7, 2006
349 Pages - SKU: AH1399190
License type:
Table of Contents Search inside this report Related Reports
Countries covered: Global

The global protein therapeutics market was valued at US$57 billion in 2005. Biotechnology has made notable inroads in the field of protein therapeutics, resulting in some of the key products presently available in the category. Recombinant proteins are potentially advantageous in terms of higher efficacy and fewer side effects than other pharmaceutical products, as they can be more specifically targeted to the cause of the disease, rather than the treatment of its symptoms.

This report examines each of the protein therapeutics classes in turn, assessing the market potential, and encompassing main therapeutic areas to which they are applicable.

The following product classes are analyzed in this report:
  • erythropoietins (EPO)
  • interferons
  • interleukins
  • insulin
  • monoclonal antibodies
  • blood-clotting factors
  • colony-stimulating factors (CSFs)
  • growth hormones
  • plasminogen activators
  • reproductive hormones
  • therapeutic enzymes
The report assesses the overall protein therapeutics market, key classes, and the factors influencing their historical and future performance. The report provides an overview of key products in each category, comparing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation by category, by region and by leading players and their products. Moreover, the report examines the promise of new drugs in each class and research and development efforts aimed at improving their delivery.

Finally, the future performance of the protein therapeutics market as a whole is examined against the background of pricing, emerging generic competition and manufacturing issues, indicating the likely trends in the coming years, and identifying possible solutions for problematic issues.

Key Features of this report:
  • Overview of the protein therapeutics environment, including main therapeutic categories, drug delivery technologies and key players
  • In-depth analysis of different classes of protein therapeutics, including key drugs in major therapeutic areas, as well as their advantages and disadvantages
  • Comprehensive facts and figures for the protein therapeutics market, including main players and regional break-downs
  • Future trends in the protein therapeutics marketplace, shaped by medical and technological advances as well as demographic and epidemiological changes and industry needs
  • Outlook for the protein therapeutics market, including manufacturing considerations and research into new methods of protein delivery
Who should buy this report?
  • Companies with a need to understand the protein therapeutics market and its place in the modern pharmaceutical industry
  • Companies interested in understanding the impact and implications of product placement, lifecycle management and competition in the protein therapeutics marketplace
  • Companies interested in understanding future opportunities in the protein therapeutics sector provided by a combination of factors, including changing demographics and financial issues
  • Pharma/biotech companies wishing to identify potential protein therapeutics areas for partnerships and collaboration in order to examine a variety of profit maximization strategies


1 Methodology, Executive Summary and Overview
1.1 Report Objectives
1.2 Research Methodology
1.3 Executive Summary
1.3.1 An Introduction to Protein Therapeutics
1.3.2 Therapeutic Applications
Table 1.1 Key Therapeutic Applications by Protein Class
1.3.3 Market Size
1.3.4 Leading Product Classes
Table 1.2 Leading Product Classes in Protein Therapeutics
Graph 1.1 Market Share of Product Classes in Protein Therapeutics
1.3.5 Leading Products
Table 1.3 Leading Products in the Protein Therapeutics Market
Graph 1.2 Percentage Change in the 2005-2010 Sales of Protein Therapeutics by Class
Graph 1.3 Leading 10 Products in the Protein Therapeutics Market by 2005 Sales
1.3.6 Market Share by Company
Table 1.4 Leading 20 Companies in Protein Therapeutics by 2005 Sales
Graph 1.4 Protein Therapeutics Market Share by Leading Companies
1.3.7 Innovation/R&D Trends

2 Challenges and Issues Facing the Therapeutic Protein Market
2.1 Pricing
2.2 Drug Delivery
2.2.1 Parenteral Delivery: Still the Leading Delivery Route for Therapeutic Proteins
Table 2.1 Main Types of Drug Delivery by Injection (Parenteral Administration)
Table 2.2 Advantages of Injectable Drug Delivery Systems Case Study: Sustainable Release Injectable Technology
Table 2.3 Key Companies in the Needleless Drug Technology Market
2.2.2 Pulmonary Delivery
2.2.3 Oral Delivery
2.3 Manufacturing Capacity Case Study: Immunex (Amgen) and Their Enbrel Shortage Case Study: Genentech
2.3.1 New Methods of Protein Manufacture
Table 2.4 Companies Involved in the Field of Transgenic Protein Technology
2.3.1.1 Transgenic Animal Production
Table 2.5 Main Methods of Creating Transgenic Animals
2.3.1.2 Protein Pharming
Table 2.6 Advantages of Avian Transgenic Technology in Protein Manufacture
2.3.1.3 Transgenic Plant Production
Table 2.7 Pros and Cons of Transgenic Plants
2.4 The Biogeneric Threat
2.4.1 Loss of Patent Protection
2.4.2 High Manufacturing Costs
2.4.3 Lack of Adequate Legislation Case Study: Biogenerics - Novartis and Omnitrope
2.4.4 Restrictive Cost of Biotech Generics
2.4.5 Biogeneric Landscape

3 Erythropoietins
3.1 Overview of Class
3.2 How Do Erythropoietins Work?
Table 3.1 Advantages and Disadvantage of Erythropoietin Therapy
3.3 Therapeutic Applications for Erythropoietins
3.3.1 Anemia
3.3.1.1 Cancer Related Anemia
3.3.1.2 Renal Anemia
3.4 Currently Marketed Products in the Class
3.4.1 Procrit/Eprex (epoetin alfa)
3.4.2 Epogen (epoetin alfa)
3.4.3 Aranesp (darbepoetin alfa)
3.4.4 NeoRecormon/Epogin (epoetin beta)
3.4.5 Espo (epoetin alfa)
3.4.6 Clinical Comparisons Between Marketed Erythropoietins
3.5 Market Analysis
3.5.1 Commercial Market Size
Table 3.2 Global Sales of Erythropoietins 1999-2005
Table 3.3 US Sales of Erythropoietins 1999-2005
Table 3.4 Non-US Sales of Erythropoietins 1999-2005
Graph 3.1 Sales of Erythropoietin Products 1999-2005, US & Rest of World
Graph 3.2 Percentage Growth of Erythropoietin Products, 2004-2005
3.5.2 Market Share by Country/Region
Graph 3.3 Market Share Erythropoietin Products, US vs Rest of World 2005
Graph 3.4 Market Share Erythropoietin Products, US vs Rest of World 2004
3.5.3 Market Share, by Product Sales
Graph 3.5 Market Share, Erythropoietin Products 2005
Graph 3.6 Market Share, Erythropoietin Products 2004
3.5.4 Market Share by Company
Graph 3.7 Company Market Share, Erythropoietin Products 2005
Graph 3.8 Company Market Share, Erythropoietin Products 2004
3.6 Key Emerging Erythropoietin Therapies
3.6.1 Dynepo
3.6.2 Mircera
3.7 Market Outlook
3.7.1 Drivers
3.7.2 Restraints
3.7.3 Financial Forecast
Table 3.5 Erythropoietin Financial Forecast 2005-2011

4 Interferons
4.1 Overview of Class
4.2 Therapeutic Uses for Interferons
4.2.1 Multiple Sclerosis
Table 4.1 Major Types of MS
4.2.2 Hepatitis
4.2.3 Leukemia
Table 4.2 Major Types of Leukemia
Table 4.3 Types of Leukemia Treatments
4.3 Classes of Interferons
4.3.1 Beta Interferons
Table 4.4 Leading MS Therapy Delivery Routes and Dosage
4.3.1.1 Avonex (interferon beta-1a)
4.3.1.2 Rebif (interferon beta-1a)
4.3.1.3 Betaferon/Betaseron (interferon beta-1b)
4.3.2 Alpha Interferons
4.3.2.1 Intron A (interferon alpha-2b)
4.3.2.2 PEG Intron (peg interferon alpha-2b)
4.3.2.3 Rebetron (interferon alpha-2b + ribavirin)
4.3.2.4 Roferon-A (interferon alpha-2a)
4.3.2.5 Alferon N (interferon alpha-n3)
4.3.2.6 Pegasys (pegylated interferon alpha-2a)
4.3.2.7 Infergen (interferon alfacon-1)
4.3.3 Gamma interferons
4.3.3.1 Actimmune
4.4 Market Analysis
4.4.1 Commercial Market Size
Graph 4.1 2005 Sales of Leading MS Therapies
Table 4.5 Global Sales of Beta Interferons 2000-2005
Table 4.6 US Sales of Beta Interferons 2000-2005
Table 4.7 Non-US Sales of Beta Interferons 2000-2005
Table 4.8 Global Sales of Alpha Interferons 2000-2005
Table 4.9 Global Sales of Gamma Interferons 2000-2005
4.4.2 Market Share by Country/Region
Graph 4.2 Country/Region Market Share Beta Interferons 2005
4.4.3 Market Share by Product Sales
Graph 4.3 Market Share Beta Interferons 2005
Graph 4.4 Market Share Alpha Interferons 2005
4.4.4 Market Share by Company
Graph 4.5 Company Market Share, Beta Interferons 2005
Graph 4.6 Company Market Share Alpha Interferons 2005
4.5 R&D Trends in the Interferon Class
4.5.1 Albuferon-Alpha
4.5.2 Tauferon
4.5.3 Interferon gamma-1b
4.5.4 Neoferon
4.5.5 Low-Dose Oral Interferon Alpha
4.6 Market Outlook
4.6.1 Drivers
4.6.2 Restraints
4.6.3 Financial Forecasts
4.6.3.1 Beta Interferon Financial Forecast
Table 4.10 Forecast Sales of Avonex
Table 4.11 Forecast Sales of Betaseron
Table 4.12 Forecast Sales of Rebif
4.6.3.2 Alpha Interferon Financial Forecast
Table 4.13 Forecast Sales of PEG-Intron
Table 4.14 Forecast Sales of Intron
Table 4.15 Forecast Sales of Pegasys
4.6.3.3 Gamma Interferon Financial Forecast
Table 4.16 Forecast Sales of Actimmune

5 Insulins
5.1 Overview of Class
5.2 How Does Insulin Work?
5.3 Therapeutic Applications
5.3.1 Diabetes
Table 5.1 Other Types of Diabetes
Table 5.2 Treatment of Types II Diabetes
5.4 Epidemiology
Table 5.3 Estimated Number of People with Diabetes
5.5 Key Products in Diabetes Treatment
Table 5.4 Types of Insulin
5.5.1 Rapid-acting
5.5.1.1 NovoRapid/Novolog (insulin aspart)
5.5.1.2 Humalog (insulin lispro)
5.5.1.3 Apidra (insulin glulisine)
5.5.1.4 NovoMix (insulin aspart mix)
5.5.2 Exubera (inhaled insulin)
5.5.3 Short-acting (regular) and intermediate-acting
5.5.3.1 Novolin (insulin)
5.5.3.2 Insuman
5.5.3.3 Humulin (insulin)
5.5.4 Long-acting
5.5.4.1 Lantus (glargine insulin)
5.5.5 Levemir (insulin determir)
Table 5.5 Relationship of A1C to Average Whole Blood and Plasma Glucose Levels
5.5.6 Iletin (insulin)
5.6 New Delivery of Insulin Stimulating Sales
Table 5.6 Patch Insulin
Table 5.7 Oral Spray Insulin
Table 5.8 Pulmonary Insulin
5.7 R&D Trends
5.7.1 NN304 (insulin detemir)
5.7.2 AERx insulin Diabetes Management System (iDMS)
5.7.3 AIR (inhaled insulin)
5.7.4 MannKind (inhaled insulin)
5.7.5 NN344
5.7.6 NN5401
5.8 Market Analysis
5.8.1 Commercial Market Size
5.8.2 Market Share by Insulin Class
Graph 5.1 Insulin Sales Segmentation by Drug Class
5.8.3 Market Share by Country/Region
Graph 5.2 Insulin Market by Country/Region
Graph 5.3 Humulin Sales by Geographical Region (2005)
Graph 5.4 Humalog Sales by Geographical Region (2005)
5.8.4 Market Share by Product Sales
Table 5.9 Insulin Product Sales (US$mn)
Graph 5.5 Insulin Market Share by Product (2005)
5.8.5 Market Share by Company
Graph 5.6 Insulin Market Share by Company
5.9 Market Outlook
Table 5.10 Forecast Insulin Product Sales
Graph 5.7 Product Sales Percentage Change 2005-2010*
5.9.1 Financial Forecast
Table 5.11 Financial Forecast for the Insulin Market
Graph 5.8 Forecast Growth of the Insulin Market (2005-2010)
5.9.2 Drivers
5.9.3 Restraints

6 Monoclonal Antibodies
6.1 Overview of Class
6.2 How do Monoclonal Antibodies Work?
6.3 Therapeutic Applications for Monoclonal Antibodies
Table 6.1 Monoclonal Antibody Therapies on the Market 2006
6.3.1 Cancer
Table 6.2 Types of Cancer
6.3.1.1 Rituxan (rituxumab)
6.3.1.2 Erbitux (cetuximab)
6.3.1.3 Herceptin (trastuzumab)
6.3.1.4 Avastin (bevacizumab)
6.3.1.5 Bexxar (tositumomab)
6.3.1.6 Mylotarg (gemtuzumab ozogamicin)
6.3.1.7 Zevalin (ibritumomab tiuxetan)
6.3.2 Autoimmune/Inflammatory Diseases
6.3.2.1 Rheumatoid Arthritis
6.3.2.1.1 Remicade (infliximab)
6.3.2.1.2 Humira (adalimumab)
6.3.2.2 Multiple Sclerosis
6.3.2.2.1 Tysabri (natalizumab)
6.3.2.3 Crohn’s Disease
6.3.2.3.1 Remicade
6.3.2.4 Psoriasis
6.3.2.4.1 Raptiva (efalizumab)
6.3.2.5 Asthma
6.3.2.5.1 Xolair
6.3.3 Age-Related Macular Degeneration (AMD)
6.3.3.1 Lucentis (ranibizumab)
6.3.4 Transplant Rejection
Table 6.3 Types of Transplant Rejection
Table 6.4 Antibodies Used to Prevent Transplant Rejection
6.3.4.1 Simulect (basiliximab)
6.3.4.2 Orthoclone OKT-3 (muromonab CD3)
6.3.5 Other Conditions
6.3.5.1 Percutaneous coronary intervention (PCI)
6.3.5.1.1 ReoPro (abciximab)
6.3.5.2 Lower Respiratory Tract Disease
6.3.5.2.1 Synagis (palivizumab)
6.4 Market Analysis
6.4.1 Commercial Market Size
Table 6.5 Leading Monoclonal Antibody Products, by Sales 2000-2005
Graph 6.1 Leading Monoclonal Antibody Products by 2005 Sales
6.4.2 Segmentation by Therapeutic Category
Graph 6.2 Monoclonal Antibody Market by Therapeutic Category (2005)
6.4.2.1 Cancer
Table 6.6 Global Sales of Monoclonal Antibodies, Cancer Indications 2003-2005
Graph 6.3 Annual Growth of Global Monoclonal Antibody Market, Cancer Indications 2003-2005
6.4.2.2 Autoimmune/Inflammatory
Table 6.7 Global Sales of Monoclonal Antibodies, Autoimmune/Inflammatory Indications, 1999-2005
Graph 6.4 Annual Growth of Global Monoclonal Antibody Market, Autoimmune/Inflammatory Indications, 1999-2005
6.4.3 Market Share by Country/Region
Table 6.8 Monoclonal Antibody Sales Market Share (2005), by Country/Region
Graph 6.5 Monoclonal Antibody Sales Market Share by Three Key Regions
6.4.4 Key Product Sales
Graph 6.6 Monoclonal Antibody Market Share, by Top Five Products
Table 6.9 Global Sales of Remicade 2000-2005
Table 6.10 Global Sales of Rituxan 2000-2005
Table 6.11 Global Sales of Herceptin 2000-2005
Table 6.12 Global Sales of Humira 2003-2005
Table 6.13 Global Sales of Avastin 2004-2005
6.4.5 Market Share by Company
Graph 6.11 Leaders in the Monoclonal Antibody Therapy Market, 2005 Market Share
6.4.6 Market Outlook
6.4.6.1 Drivers
6.4.6.2 Restraint
6.4.6.3 Financial Forecast
Table 6.14 Financial Forecast for the Monoclonal Antibody Market
6.5 Emerging Monoclonal Antibody Therapies
Table 6.15 Emerging Monoclonal Antibody Therapies
6.5.1 Herceptin (Line Extension)
6.5.2 Cotara (TNT-1)
6.5.3 Rencarex (WX-G250)
6.5.4 Humira
6.5.5 Rituxan
6.5.6 Actemra (tocilizumab)
Table 6.16 Types of ACR Response Criteria
6.5.7 Remicade
6.5.8 Tysabri
6.5.9 Segard
6.5.10 Anti-C5 antibody
6.5.11 Aurograb

7 Blood-Clotting Factors
7.1 Overview of Class
Table 7.1 Overview of Blood-Clotting Factors and Their Function
7.2 How do Blood-Clotting Factors Work?
7.3 Therapeutic Applications for Blood-Clotting Factors
7.3.1 Hemophilia
7.4 Leading Blood-Clotting Factors on the Market
Table 7.2 Leading Blood-Clotting Factors
7.4.1 NovoSeven (recombinant coagulation factor VIIa)
7.4.2 Advate (antihemophilic factor (recombinant), plasma/albumin-free method)
7.4.3 Alphanate
7.4.4 Helixate FS
7.4.5 Hemofil-M (Factor VIII)
7.4.6 Humate-P (antihemophilic factor/von Willebrand factor complex)
7.4.7 Koate HP and Koate DVI (human antihemophilic (human) factor VIII)
7.4.8 Kogenate FS (recombinant factor VIII)
7.4.9 Monarc-M
7.4.10 Monoclate-P
7.4.11 Recombinate
7.4.12 ReFacto (recombinant factor VIII)
7.4.13 AlphaNine SD
7.4.14 Bebulin VH (factor IX complex)
7.4.15 BeneFIX (recombinant factor IX)
7.4.16 Konyne 80
7.4.17 Mononine
7.4.18 Profilnine SD (systemic factor IX)
7.4.19 Proplex T (factor IX complex)
7.5 Market Analysis
7.5.1 Commercial Market Size
7.5.2 Market Share by Country/Region
Graph 7.1 Blood Clotting Market Share by Country/Region
7.5.3 Market Share by Product Sales
Table 7.3 Competing Antihemophilic Factor Brands
Table 7.4 Key Blood Clotting Factors Product Sales (US$mn)
Graph 7.2 Forecast Annual Sales Growth of Key Blood Clotting Factor Products
Graph 7.3 Blood Clotting Market Share by Factor
7.5.4 Market Share by Company
Graph 7.4 Blood Clotting Market Share by Company
7.5.5 Market Outlook
Table 7.5 Forecast Sales of Blood Clotting Factors (US$bn)
Graph 7.5 Forecast Annual Growth of Blood Clotting Factors
7.5.5.1 Drivers
7.5.5.2 Restraints
7.6 Emerging Blood-Clotting Factors
7.6.1 Bayer
7.6.2 Cell Genesys
7.6.3 Avigen
7.6.4 Novo Nordisk
7.6.5 Immune Response Corporation
7.6.6 Targeted Genetics

8 Colony-Stimulating Factors
8.1 Overview of Class
8.2 How Do Colony Stimulating Factors Work?
8.3 Therapeutic Applications for Colony Stimulating Factors
8.3.1 Chemotherapy-Induced Neutropenia
8.4 Key Colony Stimulating Factors
8.4.1 Neupogen (filgrastim)
8.4.2 Neulasta (pegfilgrastim)
8.4.3 Gran (filgrastim)
8.4.4 Leukine (sargramostim)
8.4.5 Neutrogin / Granocyte (lenograstim)
8.5 Market Analysis
8.5.1 Commercial Market Size
8.5.2 Market Share by Country/Region
Graph 8.1 CSF Market by Country/Region
8.5.3 Market Share by Product Sales
Table 8.1 Global Sales of Neupogen 1999-2005
Table 8.2 Global Sales of Neulasta 2002-2005
Graph 8.2 Global Sales of Neupogen and Neulasta 2002-2005
Graph 8.3 Global CSF Market by Product (2005)
8.5.4 Market Share by Company
Graph 8.4 Global CSF Market by Company (2005)
8.6 Market Outlook
8.6.1 Drivers
8.6.2 Restraints
8.6.3 Financial Forecast
Table 8.3 Forecast Sales of Neulasta
Table 8.4 Forecast Sales of Neupogen
Table 8.5 Forecast Sales of Colony Stimulating Factors (US$bn)
Graph 8.5 Forecast Annual Sales Growth of the CSF Market
8.7 Emerging Colony-Stimulating Factors
8.7.1 New Indications for Leukine (sargramostim)
8.7.2 Longer-acting GM-CSFs
8.7.3 PEGylated G-CSFs
8.7.4 Maxy-G34

9 Human Growth Hormones
9.1 Overview of Class
9.2 How Do Growth Hormones Work?
Table 9.1 Effects of Human Growth Hormone
9.3 Therapeutic Applications for Growth Hormones
Table 9.2 Therapeutic Applications for Growth Hormones
9.4 Key Growth Hormones
9.4.1 Genotropin (recombinant somatropin)
Table 9.3 Different Indications for Genotropin
9.4.2 Nutropin/Protropin (recombinant somatropin/somatrem)
9.4.3 Norditropin/Norditropin SimpleXx (recombinant somatropin)
9.4.4 Humatrope (recombinant somatropin)
9.4.5 Geref (sermorelin acetate)
9.4.6 Somatuline (lanreotide)
9.4.7 Saizen (somatropin)
9.4.8 Serostim (recombinant somatropin)
9.4.9 Somavert (pegvisomant)
9.4.10 Sandostatin (octreotride) and Sandostatin LAR (octreotide for injectable suspension)
Table 9.4 GH Suppression during Long-Term Treatment with Immediate Release Sandostatin Injection and Sandostatin LAR Depot
9.5 Expected Launches of Growth Hormones
9.5.1 Valtropin (somatropin)
9.5.2 Omnitrope (somatropin)
9.6 Development Pipeline for Growth Hormones
9.6.1 hGH (SkyePharma)
9.6.2 hGHD-1 (MacroMed)
9.7 Market Analysis
9.7.1 Commercial Market Size
9.7.2 Segmentation by Therapeutic Category
Graph 9.1 HGH Market Segmentation by Therapeutic Application
9.7.3 Market Share by Country/Region
Graph 9.2 HGH Market by Region (2005)
9.7.4 Market Share by Product Sales
Table 9.5 Global Sales of Key Growth Hormone Products
9.7.5 Market Share by Company
Graph 9.3 Growth Hormone Market Share by Company
9.8 Market Outlook
Table 9.6 Key Company Involvement in hGH Delivery Technology
Table 9.7 Forecast Sales of Growth Hormones
Graph 9.4 Forecast Annual Growth of Growth Hormones
9.8.1 Drivers
9.8.2 Restraints
9.9 Emerging Human Growth Hormones
9.9.1 Serostim (Serono)
9.9.2 SomatoKine (Insmed Incorporated)
9.9.3 Octreotide (QLT)
9.9.4 ALX1-11 (NPS Pharmaceuticals)
9.9.5 Geref (Serono)
9.9.6 Leptin (Amgen)

10 Interleukins
10.1 Overview of Class
10.2 How Do Interleukins Work?
10.3 Types of Interleukins and Their Functions
Table 10.1 Interleukins, Major Sources and Effects
10.4 Therapeutic Applications for Interleukins
10.4.1 Cancer
10.4.2 Human immunodeficiency virus (HIV)
10.4.3 Transplantation
10.5 Key Interleukin Products on Market
10.5.1 Interleukin-1
10.5.2 Interleukin-2
10.5.2.1 Proleukin (aldesleukin)
10.5.2.2 Ontak (denileukin deftitox)
10.5.2.3 Imunace (celmoleukin)
10.5.3 Interleukin 11
10.5.3.1 Neumega (oprelvekin)
10.6 Market Analysis
10.6.1 Commercial Market Size
10.6.2 Segmentation by Therapeutic Category
Graph 10.1 Interleukin Market Segmentation by Therapeutic Category
10.6.3 Market Share by Country/Region
Graph 10.2 Interleukin Market Segmentation by Country/Region
10.6.4 Market Share by Product Sales
Table 10.2 Global Sales of Key Interleukins
Graph 10.3 Interleukins Market by Product Sales
10.6.5 Market Share by Company
Graph 10.4 Market Share by Company
10.7 Market Outlook
Table 10.3 Forecast Sales of Interleukins (US$mn)
Graph 10.5 Forecast Annual Sales Growth of Interleukins
10.7.1 Drivers
10.7.2 Restraints
10.8 Emerging Interleukins
10.8.1 IL-11 - Neumega (oprelvekin)
10.8.2 New Indication for Proleukin (aldesleukin)
10.8.3 Interleukin-12
10.8.4 Cytoryn (IL-2 controlled release injectable depot)
10.8.5 Interleukin-6 (Sigosix)
10.8.6 Interleukin-4
10.8.7 Interleukin-1
10.8.8 Recombinant IL-10
10.8.9 Prestara

11 Plasminogen Activators
11.1 Overview of Class
Table 11.1 Embolism and Its Outcomes
11.2 How Do Plasminogen Activators Work?
Table 11.2 Brand Names of PAs
11.3 Therapeutic Applications for Plasminogen Activators
11.3.1 Heart Attack
11.3.2 Stroke
11.3.3 Pulmonary Embolism
11.4 Key Plasminogen Activators on Market
11.4.1 Activase (alteplase)
11.4.2 Actilyse (alteplase)
11.4.3 Abbokinase (urokinase)
11.4.4 Rapilysin/Retavase (reteplase)
11.4.5 TNKase (tenecteplase)
11.4.6 Metalyse (tenecteplase)
11.4.7 Streptase (streptokinase)
11.5 Market Analysis
11.5.1 Commercial Market Size
11.5.2 Segmentation by Therapeutic Category
Graph 11.1 Plasminogen Activators Market Share by Therapeutic Application
11.5.3 Market Share by Country/Region
Graph 11.2 Plasminogen Activators Market Segmentation by Country/Region
11.5.4 Market Share by Product Sales
Graph 11.3 Plasminogen Activators Market Share by Product Sales
Graph 11.4 Global Sales of Genentech's PAs (US$mn)*
11.5.5 Market Share by Company
Graph 11.5 Plasminogen Activators Market Share by Company
11.6 Market Outlook
Table 11.3 Forecast Sales of Plasminogen Activators
Graph 11.6 Forecast Annual Sales Growth of Plasminogen Activators
11.6.1 Drivers
11.6.2 Restraints
11.7 Emerging Plasminogen Activators
11.7.1 Solinase (pamiteplase)
11.7.2 Alfimeprase
11.7.3 Lanoteplase

12 Reproductive Hormones
12.1 Overview of Class
Table 12.1 Overview of Reproductive Hormones
12.2 How do Reproductive Hormones Work? Figure 12.1 Simplified
Graphic Representation of Normal Gonadal Function
12.3 Therapeutic Applications for Reproductive Hormones
Table 12.2 Reproductive Hormones and Their Therapeutic Applications
12.3.1 Osteoporosis
Table 12.3 FDA-Approved Bisphosphonates for the Treatment of Osteoporosis in Post-Menopausal Women
12.3.2 Cancer
Table 12.4 Incidence and Death Rates of Cancer in the US (Male and Female)
12.3.3 Menopause-Related Conditions
Table 12.5 Hormone Therapy Regimes
12.3.4 Male Sexual Dysfunctions
12.3.5 Infertility
Table 12.6 Medications for the Treatment of Infertility
12.3.6 Contraception
12.4 Leading Reproductive Hormones on the Market
12.4.1 Gonadotropins
12.4.2 Hormone Replacement Therapy
12.4.3 Estrogens and Progestins
Table 12.7 FDA-Approved Estrogens/Hormones for the Treatment of Osteoporosis
12.5 Market Analysis
12.5.1 Commercial Market Size
12.5.2 Segmentation by Therapeutic Category
Graph 12.1 Segmentation of Hormone Replacement Market by Therapeutic Category
12.5.3 Market Share by Country/Region
Graph 12.2 Reproductive Hormones Market Segmentation by Country/Region
12.5.4 Market Share by Product Sales
Table 12.8 Sales of Key Gonadotropins in US (2003-2005)
Graph 12.3 Global Sales of Key Gonadotropins
Table 12.9 Global Sales of Key HRT Products in US$mn (2003-2005)
Graph 12.4 Annual Growth of HRT Product Sales
Table 12.10 Global Sales of Johnson & Johnson's Hormonal Contraceptives in US$mn (2003-2005)
Table 12.11 Global Sales of Schering AG's Hormonal Contraceptives in US$mn (2004-2005)
12.5.5 Market Share by Company
12.6 Market Outlook
Table 12.12 Forecast Sales of Reproductive Hormones
Graph 12.5 Forecast Annual Sales Growth of Reproductive Hormones
12.6.1 Drivers
12.6.2 Restraints
12.7 Emerging Reproductive Hormones
12.7.1 Ophena (ospemifene)
12.7.2 Bazedoxifene
12.7.3 Oporia (lasofoxifeneEmerging Reproductive Hormones)

13 Enzyme Replacement
13.1 Overview of Class
13.2 How does Enzyme Replacement Work?
13.3 Therapeutic Applications for Enzyme Replacement
13.3.1 Lysosomal storage disorders
13.3.2 Fabry Disease
13.3.3 Gaucher Disease
13.3.4 Mucopolysaccharidoses (MPSs)
Table 13.1 Types of Mucopolysaccharidosis
13.3.5 Infantile Pompe Disease (IPD)
13.4 Leading Enzyme Replacement Therapies on the Market
13.4.1 Fabrazyme (agalsidase beta)
13.4.2 Ceredase (alglucerase)
13.4.3 Cerezyme (imiglucerase)
13.4.4 Myozyme (alglucosidase alfa)
13.4.5 Elaprase (idursulfase)
13.4.6 Naglazyme (galsulfase)
13.4.7 Aldurazyme (laronidase)
13.5 Market Analysis
13.5.1 Commercial Market Size
13.5.2 Segmentation by Therapeutic Category
Graph 13.1 ERT Market Segmentation by Therapeutic Category
13.5.3 Market Share by Country/Region
Graph 13.2 ERT Market Segmentation by Country/Region
13.5.4 Market Share by Product Sales
Table 13.2 Global Sales of Key Enzyme Replacement Products
Graph 13.3 Global Sales of Key Enzyme Replacement Products
13.5.5 Market Share by Company
Graph 13.4 ERT Market by Company
Table 13.3 Key Companies Involved in the ERT Market
13.6 Market Outlook
Table 13.4 Forecast Sales of ERT Market (US$bn)
Graph 13.5 Forecast Annual Sales Growth of the ERT Market
13.6.1 Drivers
13.6.2 Restraints
13.7 Emerging Enzyme Replacement Therapies
13.7.1 AGT-180
13.7.2 Phex
13.7.3 ENZAGAL
13.7.4 rhASB

14 Company Profiles
14.1 Abbott Laboratories
14.2 Amgen
14.3 Amylin Pharmaceuticals
14.4 Anika Therapeutics
14.5 ArmaGen Technologies
14.6 Biogen Idec
Table 14.1 Biogen Idec’s Oncology Pipeline
14.7 BioMarin Pharmaceutical
14.8 BioMimetic Therapeutics
14.9 Bolder BioTechnology
14.10 Boston Life Sciences
14.11 Cambrex
14.12 Cambridge Antibody Technology
14.13 Ceregene
14.14 Chiron Corporation
Table 14.2 Chiron’s Oncology Pipeline
14.15 Chugai Pharmaceutical
Table 14.3 Chugai’s Oncology Pipeline
14.16 Coley Pharmaceutical Group
14.17 CuraGen
14.18 Curis Inc
14.19 Dragon Pharmaceuticals
14.20 Enobia
14.21 Enzon
Table 14.4 Enzon Drug Delivery Portfolio, 2006
14.22 Eyetech Pharmaceuticals
14.23 FibroGen
14.24 FzioMed
14.25 GeneMedix
14.26 Genentech
14.27 Genmab
14.28 GenSci Regeneration Sciences
14.29 Genvec
14.30 Genzyme
14.31 Human Genome Sciences
14.32 ImClone Systems
14.33 Insmed
14.34 Janssen-Ortho
14.35 Johnson & Johnson
14.36 Maxygen
14.37 Medarex
Table 14.5 Medarex’s Oncology Pipeline
14.38 MedImmune
14.39 OSI Pharmaceuticals
14.40 PeproTech
14.41 PDL Biopharma
14.42 Protein Polymer Technology
14.43 Raven Biotechnologies
14.44 Regeneron Pharmaceuticals
14.45 Rentschler Biotechnologie
14.46 Roche
14.47 Sangamo Biosciences
14.48 Scil Proteins
14.49 Serono
14.50 Spectrum Pharmaceuticals
14.51 Seattle Genetics
14.52 Stryker Biotech
14.53 Theratechnologies
14.54 Transition Therapeutics
14.55 Vernalis Pharmaceuticals
14.56 Wockhardt
Table 14.7 Wockhardt’s Biopharmaceutical Pipeline
14.57 Wyeth
14.58 Xoma
14.59 ZymoGenetics

More Antibody Technologies reports by Arrowhead Publishers

Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight by Arrowhead Publishers
In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24 percent of the total protein therapeutics market. This share ...
See all reports like this >>

More Global Antibody Technologies reports

Single-Use Technologies for Biopharmaceuticals: Global Markets by BCC Research
This report provides: An overview of biopharmaceutical single-use technologies, which aids the manufacturing process in overcoming such complex issues as sterilization and critical manufacturing parameters ...
Global Monoclonal Antibodies Market 2011-2015 by Infiniti Research Limited
TechNavio's analysts forecast the Global Monoclonal Antibodies market to grow at a CAGR of 10.6 percent over the period 2011-2015. One of the key factors ...
Global Kinase Inhibitors Market 2011-2015 by Infiniti Research Limited
TechNavio's analysts forecast the Global Kinase Inhibitor market to grow at a CAGR of 6.4 percent over the period 2011-2015. One of the key factors ...
Global Biopharmaceutical Market Report & Forecast (2012-2017) by IMARC
The global biopharmaceutical Industry has come a long way since its first drug - Humulin was approved in 1982. Today more than three hundred biopharmaceuticals ...
See all reports like this >>

 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Related Markets


Antibody Technologies Reports

 
 

Share this report


Other tasks

 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!